X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the collaboration, Araris will use its proprietary linker-conjugation platform to generate next-generation novel ADCs against undisclosed targets provided by Taiho.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Taiho Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 08, 2023
Details:
Araris’ awarded grant will be used to support further development and advancement of Araris’ antibody-drug conjugate (ADC) candidates. Araris’ ADC linker technology enables payload attachment to off the shelf antibodies without needing to re-engineer or reduce antibodies.
Lead Product(s): Antibody-drug Conjugate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Innosuisse
Deal Size: $2.8 million Upfront Cash: Undisclosed
Deal Type: Funding May 05, 2023
Details:
Araris intends to use the antibody in the development of a differentiated Nectin-4 ADC using its proprietary linker technology to broaden its Antibody-drug Conjugate pipeline.
Lead Product(s): Antibody-drug Conjugate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: ARS Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 17, 2023
Details:
The net proceeds will be used to support further development and advancement of Araris’ antibody-drug conjugate candidates using company's proprietary antibody-drug conjugate (ADC)-linker technology.
Lead Product(s): Antibody Drug Conjugate
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Samsung Venture Investment Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing April 11, 2023
Details:
ARC-02 demonstrated potent cytotoxicity in three different non-Hodgkin Lymphoma (NHL) cell lines, with similar potency to Polivy® despite ARC-02’s having a lower drug load.
Lead Product(s): ARC-02
Therapeutic Area: Oncology Product Name: ARC-02
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2023
Details:
Proceeds from the financing will be used to support the further development and advancement of Araris’ antibody-drug conjugate (ADC) candidates, created using the Company’s proprietary linker technology, as Araris moves closer towards clinical development.
Lead Product(s): Antibody-drug Conjugate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: 4BIO Capital
Deal Size: $24.0 million Upfront Cash: Undisclosed
Deal Type: Financing October 04, 2022
Details:
The resulting ADC-based Therapeutic have shown very high activity at low doses and an improved therapeutic index compared to multiple FDA-approved ADCs.
Lead Product(s): ADC-based Therapeutic
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2022
Details:
The poster presentation highlights the company’s anti-CD79b antibody-drug conjugate contains polatuzumab (non-engineered) as targeting antibody and monomethyl auristatin E as payload highlight late-breaking data on a Nectin-4 ADC.
Lead Product(s): Polatuzumab-monomethyl auristatin E
Therapeutic Area: Oncology Product Name: Nectin-4 ADC
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
The poster will highlight preclinical data from Araris’ anti-CD79b antibody-drug conjugate (ADC) program, and the company will also present data on a Nectin-4 ADC. The company’s ADCs were built using Araris’ proprietary peptide linker technology.
Lead Product(s): Antibody Drug Conjugate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2022
Details:
ARC-01 showed superior anti-tumor efficacy in a head-to-head study compared to the FDA-approved polatuzumab vedotin (PV) using the identical antibody sequence and payload.
Lead Product(s): ARC-01
Therapeutic Area: Oncology Product Name: ARC-01
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
